P/B
20,3
Amgen
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
$237.5B
Market Cap • 10/23/2026
1980
(46 years)
Founded
1983
(43 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
S&P500 Participant
Index Composite • 2026
Valuation
P/S
6,2
P/EBITDA
14,8
P/OCF
19
P/FCF
23,3
P/E
27,3
BVPS
21,6
EPS
16,1
Market Cap
Market Cap
237,5B
EV
280,8B
EV/Revenue
7,4
EV/EBITDA
17,4
EV/EBIT
24,6
Payout
Dividend Per Share
9,8
Dividend Yield
2,3%
Buyback Yield
0%
Total Yield
2,3%
Dividend Yield 5Y
2,9%
Payout
60,4%
Retained Earnings
-22,3B
Profitability
Gross Margin
69,5%
EBITDA Margin
42,2%
EBIT Margin
30%
Net Margin
23%
D&A/EBITDA
0%
R&D/Revenue
20%
Capex/Revenue
6%
Capex/D&A
49,3%
Capex/OCF
18,5%
SBC/OCF
3,9%
% PPE
8,9%
% Goodwill
19,5%
ROE
91,5%
ROIC
15%
Growth
CAGR Revenue 5Y
8,4%
CAGR Op. Income 5Y
9%
CAGR Net Income 5Y
8,8%
CAGR EPS 5Y
10,4%
CAGR OCF 5Y
5,5%
Leverage
N.D./EBITDA
2,7
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
0,9
Interest Coverage
428,3%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!